Skip to main content
. 2008 Sep 21;1:42. doi: 10.1186/1755-8794-1-42

Table 2.

Published breast cancer datasets used in this study.

Datasets No. Tumours Array express/GEO ID GeneChip ER+ Age Tumour Size (cm) FU (years) Reference
Chin et al. 2006 114 E-TABM U133AA 67% 51 2.3 6.1 [16]
Desmedt et al. 2007 198 GSE7390 U133A 68% 47 2.0 13.6 [17]
Farmer et al 2005 49 GSE1561 U133A 58% - - - [11]
Ivshina et al. 2006 249 GSE4922 U133A 85% 63 2.0 9.9 [18]
Loi et al. 2007 119, 87 GSE6532 U133A, U133 plus2.0 100% 65, 62 2.4, 2.1 5.2, 11.4 [32]
Minn et al. 2007 58 GSE5327 U133A 0% - - 7.2 [33]
Pawitan et al. 2005 159 GSE1456 U133A 83% 58$ 2.2$ 7.1 [19]
Richardson et al. 40 GSE3744 U133 plus2.0 38% - - - [10]
Sotiriou et al. 2006 101* GSE2990 U133A 71% 60 2.0 5.8 [20]
Wang et al. 2005 286 GSE2034 U133A 73% 52 - 7.2 [52]

Continuous variables (age, size and follow up) are given as median values, except where indicated $ the mean was given. The follow up (FU) endpoints for the datasets Loi et al, Pawitan et al. and Sotoriou et al were recurrence-free survival, for datasets Desmedt et al. and Ivshina et al. it was disease-free survival and for datasets Minn et al. and Wang et al. it was distant metastasis-free survival. *The full dataset of Sotiriou et al. includes 189 tumours, but 88 of the Uppsala tumours are included in dataset Ivshina et al.